Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 17

1.

NMDA receptor subunits and associated signaling molecules mediating antidepressant-related effects of NMDA-GluN2B antagonism.

Kiselycznyk C, Jury NJ, Halladay LR, Nakazawa K, Mishina M, Sprengel R, Grant SG, Svenningsson P, Holmes A.

Behav Brain Res. 2015;287:89-95. doi: 10.1016/j.bbr.2015.03.023. Epub 2015 Mar 21.

2.

Adult AMPA GLUA1 receptor subunit loss in 5-HT neurons results in a specific anxiety-phenotype with evidence for dysregulation of 5-HT neuronal activity.

Weber T, Vogt MA, Gartside SE, Berger SM, Lujan R, Lau T, Herrmann E, Sprengel R, Bartsch D, Gass P.

Neuropsychopharmacology. 2015 May;40(6):1471-84. doi: 10.1038/npp.2014.332. Epub 2014 Dec 30.

3.

What causes aberrant salience in schizophrenia? A role for impaired short-term habituation and the GRIA1 (GluA1) AMPA receptor subunit.

Barkus C, Sanderson DJ, Rawlins JN, Walton ME, Harrison PJ, Bannerman DM.

Mol Psychiatry. 2014 Oct;19(10):1060-70. doi: 10.1038/mp.2014.91. Epub 2014 Sep 16. Review.

4.

Construction and analysis of the protein-protein interaction networks based on gene expression profiles of Parkinson's disease.

Rakshit H, Rathi N, Roy D.

PLoS One. 2014 Aug 29;9(8):e103047. doi: 10.1371/journal.pone.0103047. eCollection 2014.

5.

Chronic treatment with mood-stabilizers attenuates abnormal hyperlocomotion of GluA1-subunit deficient mice.

Maksimovic M, Vekovischeva OY, Aitta-aho T, Korpi ER.

PLoS One. 2014 Jun 16;9(6):e100188. doi: 10.1371/journal.pone.0100188. eCollection 2014.

6.

Alterations of the myristoylated, alanine-rich C kinase substrate (MARCKS) in prefrontal cortex in schizophrenia.

Pinner AL, Haroutunian V, Meador-Woodruff JH.

Schizophr Res. 2014 Apr;154(1-3):36-41. doi: 10.1016/j.schres.2014.02.003. Epub 2014 Feb 22.

7.

Deletion in the N-terminal half of olfactomedin 1 modifies its interaction with synaptic proteins and causes brain dystrophy and abnormal behavior in mice.

Nakaya N, Sultana A, Munasinghe J, Cheng A, Mattson MP, Tomarev SI.

Exp Neurol. 2013 Dec;250:205-18. doi: 10.1016/j.expneurol.2013.09.019. Epub 2013 Oct 2.

8.

Reduced phosphorylation of GluA1 subunits relates to anxiety-like behaviours in mice.

Kiselycznyk C, Zhang X, Huganir RL, Holmes A, Svenningsson P.

Int J Neuropsychopharmacol. 2013 May;16(4):919-24. doi: 10.1017/S1461145712001174. Epub 2013 Jan 29.

9.

GluN1 hypomorph mice exhibit wide-ranging behavioral alterations.

Barkus C, Dawson LA, Sharp T, Bannerman DM.

Genes Brain Behav. 2012 Apr;11(3):342-51. doi: 10.1111/j.1601-183X.2012.00767.x. Epub 2012 Feb 9.

10.

Comprehensive neurocognitive endophenotyping strategies for mouse models of genetic disorders.

Hunsaker MR.

Prog Neurobiol. 2012 Feb;96(2):220-41. doi: 10.1016/j.pneurobio.2011.12.001. Epub 2012 Jan 13. Review.

11.

Stress-induced deficits in cognition and emotionality: a role of glutamate.

Graybeal C, Kiselycznyk C, Holmes A.

Curr Top Behav Neurosci. 2012;12:189-207. Review.

12.

Pharmacological modulation of stress-induced behavioral changes in the light/dark exploration test in male C57BL/6J mice.

Ihne JL, Fitzgerald PJ, Hefner KR, Holmes A.

Neuropharmacology. 2012 Jan;62(1):464-73. doi: 10.1016/j.neuropharm.2011.08.045. Epub 2011 Sep 2.

13.

Glycogen synthase kinase-3 in the etiology and treatment of mood disorders.

Jope RS.

Front Mol Neurosci. 2011 Aug 9;4:16. doi: 10.3389/fnmol.2011.00016. eCollection 2011.

14.

Circadian rhythms and mood regulation: insights from pre-clinical models.

McClung CA.

Eur Neuropsychopharmacol. 2011 Sep;21 Suppl 4:S683-93. doi: 10.1016/j.euroneuro.2011.07.008. Epub 2011 Aug 11. Review.

15.

Genetic, pharmacological and lesion analyses reveal a selective role for corticohippocampal GLUN2B in a novel repeated swim stress paradigm.

Kiselycznyk C, Svenningsson P, Delpire E, Holmes A.

Neuroscience. 2011 Oct 13;193:259-68. doi: 10.1016/j.neuroscience.2011.06.015. Epub 2011 Jun 23.

16.

Do GluA1 knockout mice exhibit behavioral abnormalities relevant to the negative or cognitive symptoms of schizophrenia and schizoaffective disorder?

Barkus C, Feyder M, Graybeal C, Wright T, Wiedholz L, Izquierdo A, Kiselycznyk C, Schmitt W, Sanderson DJ, Rawlins JN, Saksida LM, Bussey TJ, Sprengel R, Bannerman D, Holmes A.

Neuropharmacology. 2012 Mar;62(3):1263-72. doi: 10.1016/j.neuropharm.2011.06.005. Epub 2011 Jun 15.

17.

New translational assays for preclinical modelling of cognition in schizophrenia: the touchscreen testing method for mice and rats.

Bussey TJ, Holmes A, Lyon L, Mar AC, McAllister KA, Nithianantharajah J, Oomen CA, Saksida LM.

Neuropharmacology. 2012 Mar;62(3):1191-203. doi: 10.1016/j.neuropharm.2011.04.011. Epub 2011 Apr 21. Review.

Items per page

Supplemental Content

Write to the Help Desk